STRATEC SE : Q3 review – Weak preliminary results, slight guidance cut
>Weak third quarter on top and bottom line - Stratec reported preliminary Q3 results which showed a weaker-than-expected sales performance in the third quarter. Q3 revenues of € 57m (-8.7% y-o-y) fell short of our expectations by 12% and by 15% of the consensus. The company reported an adjusted EBIT level of € 5.1m, which was 20% below our forecast and 23% below the consensus. We acknowledge that the consensus quality does not seem to look well. Stratec stated that th...STRATEC Biomedical designs and manufactures automation solutions and technologies for use mainly in in-vitro diagnostics (IVD) and in other regulated markets. IVD refers to those diagnostics activities performed outside the body in a glass or in test receptacles in a laboratory. Co. operates through two segments: Instrumentation and All Other. In the Instrumentation segment, Co. designs and manufactures fully automated analyzer systems for its clinical diagnostics and biotechnology customers. In its all other segment, Co. develops workflow software for networking several analyzer systems and develops and sells scientific materials and technologies such as nucleic acid purification.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.